標(biāo)題: Titlebook: Drug Development in Psychiatry; Matthew Macaluso,Sheldon H. Preskorn,Richard C. Sh Book 2023 The Editor(s) (if applicable) and The Author( [打印本頁(yè)] 作者: CROSS 時(shí)間: 2025-3-21 17:50
書目名稱Drug Development in Psychiatry影響因子(影響力)
書目名稱Drug Development in Psychiatry影響因子(影響力)學(xué)科排名
書目名稱Drug Development in Psychiatry網(wǎng)絡(luò)公開度
書目名稱Drug Development in Psychiatry網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Development in Psychiatry被引頻次
書目名稱Drug Development in Psychiatry被引頻次學(xué)科排名
書目名稱Drug Development in Psychiatry年度引用
書目名稱Drug Development in Psychiatry年度引用學(xué)科排名
書目名稱Drug Development in Psychiatry讀者反饋
書目名稱Drug Development in Psychiatry讀者反饋學(xué)科排名
作者: Indecisive 時(shí)間: 2025-3-21 20:54 作者: 愛(ài)社交 時(shí)間: 2025-3-22 01:26 作者: TATE 時(shí)間: 2025-3-22 05:47
https://doi.org/10.1007/978-3-663-11765-0velopment, it is important to first understand the history of psychiatry including early attempts at drug discovery and develoment. The early history of psychiatry is mired with the use of inhumane experimental treatments and the institutionalization of patients in asylums. Some of the earliest drug作者: 藥物 時(shí)間: 2025-3-22 11:26
Integrationstheorie und Mehrebenenpolitik,al models have been essential in the in vivo validation of novel drug targets, establishment of lead compound pharmacokinetic to pharmacodynamic relationships, optimization of lead compounds through preclinical candidate selection, and development of translational measures of target occupancy and fu作者: 表被動(dòng) 時(shí)間: 2025-3-22 16:34
Grundkonzepte der Programmierung and neurodegenerative disorders such as depression, ADHD, neuropathic pain, anxiety disorders, stimulant use disorders, epilepsy, and Parkinson’s disease. The MAT family is comprised of three main members – the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin tran作者: 表被動(dòng) 時(shí)間: 2025-3-22 18:55 作者: FRONT 時(shí)間: 2025-3-22 22:17
Grundkonzepte der Programmierunghic and comorbid clinical characteristics. Is this medicine more effective, safe, tolerable, or affordable than the options used in the past? A payer may ask if the new medication offers a more effective, cost-efficient, or convenient alternative to those treatments already being covered. These are 作者: gene-therapy 時(shí)間: 2025-3-23 03:53
Objektorientierte Programmierungrom investments diverted to other therapeutic areas to reduced reliance on efficacy claims derived from preclinical models. In this chapter, we argue that there are several existing examples that teach us on what needs to be done to improve the success rate. We advocate the reverse engineering appro作者: Ballad 時(shí)間: 2025-3-23 07:23 作者: Cabg318 時(shí)間: 2025-3-23 10:07 作者: PLAYS 時(shí)間: 2025-3-23 16:11 作者: hazard 時(shí)間: 2025-3-23 18:14
,Rechnergestützte Vorrichtungskonstruktion, for the central nervous system (CNS). In preclinical studies and both early- and late-phase human trials, fMRI has the potential to improve cross-species translation of drug effects, help to de-risk compounds early in development, and contribute to the portfolio of evidence for a compound’s efficac作者: 雜色 時(shí)間: 2025-3-23 22:34 作者: Flat-Feet 時(shí)間: 2025-3-24 05:51 作者: Daily-Value 時(shí)間: 2025-3-24 06:34
Hans Rosenkranz,Reinhard Breuelior, increased endogenous inflammation has received attention as one pathophysiologic process contributing to psychiatric illnesses and particularly depression. Increased endogenous inflammation is observed in a significant proportion of depressed patients and has been associated with reduced respon作者: 花爭(zhēng)吵 時(shí)間: 2025-3-24 11:40 作者: Mawkish 時(shí)間: 2025-3-24 16:07 作者: 雄偉 時(shí)間: 2025-3-24 22:23 作者: 斜 時(shí)間: 2025-3-25 01:23
Drug Development in Psychiatry978-3-031-21054-9Series ISSN 2190-5215 Series E-ISSN 2190-5223 作者: incision 時(shí)間: 2025-3-25 04:45 作者: 刺激 時(shí)間: 2025-3-25 08:20 作者: 帶子 時(shí)間: 2025-3-25 15:00
Reverse Engineering Drugs: Lorcaserin as an Example,作者: Stress 時(shí)間: 2025-3-25 17:42 作者: progestin 時(shí)間: 2025-3-25 21:14
Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Develophanism of action: blockade of the glutamate NMDA receptor. These studies coupled with earlier studies with other NMDA drugs suggest approximately 60% of patient with TRD are rapidly and robustly responsive to this mechanism of action. Thus, there appears to be three forms of MD based on pharmacologi作者: 沒(méi)有準(zhǔn)備 時(shí)間: 2025-3-26 00:23 作者: 易受刺激 時(shí)間: 2025-3-26 07:41 作者: 無(wú)動(dòng)于衷 時(shí)間: 2025-3-26 10:12
Discovery and Development of Monoamine Transporter Ligands, result in their behavioral effects. This review focusses on recent examples of ligand-based structure-activity relationship studies trying to overcome some of the challenges associated with previously developed MAT inhibitors. These studies have led to the discovery of unique and novel structurally作者: 樹木中 時(shí)間: 2025-3-26 14:36 作者: PAC 時(shí)間: 2025-3-26 17:17 作者: 吸引人的花招 時(shí)間: 2025-3-26 22:00
Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics,guide the development of novel therapeutics. These studies suggest that the use of objective physiological data is poised to alter the landscape of psychiatric diagnosis and treatment. However, practical and economic barriers remain as major hurdles. The key to finding such translational diagnostic 作者: 陶瓷 時(shí)間: 2025-3-27 05:05
The Role of fMRI in Drug Development: An Update,d challenges faced in its utilization, and ends with directions for future development of capabilities in this arena. This chapter is the 5-year update of material from a previously published workshop summary (Carmichael et al., Drug DiscovToday 23(2):333–348, 2018).作者: Genetics 時(shí)間: 2025-3-27 06:05 作者: 哀悼 時(shí)間: 2025-3-27 09:56
Genomics in Treatment Development,ance to CNS disorders. The environment can induce chemical modifications of DNA (e.g., cytosine methylation), which can be induced by the environment and may represent either shorter- or longer-term changes. Given the importance of environmental influences on CNS disorders, epigenetics may identify 作者: Chivalrous 時(shí)間: 2025-3-27 15:41 作者: aggrieve 時(shí)間: 2025-3-27 19:19
Die Arbeit mit der virtuellen Maschine,hanism of action: blockade of the glutamate NMDA receptor. These studies coupled with earlier studies with other NMDA drugs suggest approximately 60% of patient with TRD are rapidly and robustly responsive to this mechanism of action. Thus, there appears to be three forms of MD based on pharmacologi作者: deforestation 時(shí)間: 2025-3-28 01:26
https://doi.org/10.1007/978-3-663-11765-0ail about each of these psychotropic drugs, the events leading up to their discovery, and their role in formulating the biological basis of mental disorders including schizophrenia, depression, and bipolar disorder. Psychiatry, it seems has worked its way backwards from first identifying treatments 作者: CLASP 時(shí)間: 2025-3-28 04:42
Integrationstheorie und Mehrebenenpolitik,as undergone a dynamic evolution with the application of the Research Domain Criteria (RDoC) framework for better design of preclinical to clinical translational studies combined with innovative genetic, neural circuitry-based, and automated testing technologies. In this chapter, the authors will di作者: 正論 時(shí)間: 2025-3-28 07:31 作者: 同謀 時(shí)間: 2025-3-28 14:11 作者: 善變 時(shí)間: 2025-3-28 17:25 作者: 惡意 時(shí)間: 2025-3-28 19:02 作者: 戲服 時(shí)間: 2025-3-29 01:35
,Rechnergestützte Vorrichtungskonstruktion,d challenges faced in its utilization, and ends with directions for future development of capabilities in this arena. This chapter is the 5-year update of material from a previously published workshop summary (Carmichael et al., Drug DiscovToday 23(2):333–348, 2018).作者: 公社 時(shí)間: 2025-3-29 03:26 作者: Mosaic 時(shí)間: 2025-3-29 08:37 作者: resilience 時(shí)間: 2025-3-29 13:59
Hans Rosenkranz,Reinhard Breuelects on the brain and behavior will be discussed in the context of a need for intelligent trial design in order to meaningfully translate these concepts and develop more precise therapies for depressed patients with increased inflammation.作者: 跑過(guò) 時(shí)間: 2025-3-29 18:52
Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Develop present and then looks forward to the future. It begins with the chance discovery drugs and then moves to through their rational refinement using structure activity relationships to narrow the pharmacological actions of the drugs to those mediating their antidepressant effects and eliminating the e作者: 隱士 時(shí)間: 2025-3-29 20:45 作者: irradicable 時(shí)間: 2025-3-30 01:43
The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiaal models have been essential in the in vivo validation of novel drug targets, establishment of lead compound pharmacokinetic to pharmacodynamic relationships, optimization of lead compounds through preclinical candidate selection, and development of translational measures of target occupancy and fu作者: 諷刺 時(shí)間: 2025-3-30 07:18 作者: 嫻熟 時(shí)間: 2025-3-30 08:43 作者: 外來(lái) 時(shí)間: 2025-3-30 16:01
Post-Approval Research in Drug Development: Priorities and Practices,hic and comorbid clinical characteristics. Is this medicine more effective, safe, tolerable, or affordable than the options used in the past? A payer may ask if the new medication offers a more effective, cost-efficient, or convenient alternative to those treatments already being covered. These are 作者: 貨物 時(shí)間: 2025-3-30 17:05 作者: Folklore 時(shí)間: 2025-3-30 21:35
Targeted Treatments for Fragile X Syndrome,neurobiology of FXS have identified a number of pathways that are dysregulated in the absence of FMRP and are therefore pathways that can be targeted with new medication. The utilization of quantitative outcome measures to assess efficacy in multiple studies has improved the quality of more recent t作者: 小鹿 時(shí)間: 2025-3-31 01:34
The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders,tments with the potential to have a significant impact on human health. CNS diseases, however, present particular challenges to therapeutic discovery efforts, and psychiatric diseases/disorders may be among the most difficult. With specific exceptions such as psychostimulants for ADHD, a large numbe作者: 易于出錯(cuò) 時(shí)間: 2025-3-31 08:12 作者: indemnify 時(shí)間: 2025-3-31 09:23 作者: 毛細(xì)血管 時(shí)間: 2025-3-31 13:45 作者: Mercurial 時(shí)間: 2025-3-31 18:49
